GRK4 Polymorphisms Blood Pressure Response to Candesartan
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.
Also called NCT01629225
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 500 participants
- Registry
-
NCT01629225
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01629225. Allocation not applicable; single masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2015-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GRK4 Polymorphisms Blood Pressure Response to Candesartan
- Condition
- Essential Hypertension
- Intervention (Drug)
- Candesartan
- Lead sponsor
- Third Military Medical University
Record details
- Record id
cardio:ct-nct01629225- Content hash
2e6c4c8074675881ba65816f7801106c66de4360a303be78b6f7fd23737773fd